PMC2633270_01
PMC2633270_02
Relationship between somatotropin administration, MRI, clinical outcome, and steroid administration. Growth hormone administration was related to both MRI changes and a worse clinical performance. Dexamethasone administration produced no amelioration, either clinical or visible in the MRI. This was achieved instead by first suspending somatotropin, then restoring it at lower doses.
1752-1947-3-17-1.jpg
PMC2633270_02_1752-1947-3-17-1.jpg
F1
November 2005, June 2006, December 2006, July 2007, and March 2008 (Figures 1 and 2). No recurrent disease was documented by these MRI studies, and the girl is currently in continuous complete response.
Iconography strongly suggests an association between growth hormone administration and proinflammatory activity. Axial MRI images immediately before administering growth hormone, after 3 months of growth hormone administration, 3 months after suspending growth hormone, and after 15 months of lower-dose administration of growth hormone. The areas of focal enhancement in the images taken before the therapy with growth hormone reveal inflammation and necrosis, an expression of post-therapy alterations. After 3 months of growth hormone therapy, the main finding is an increase in the perifocal edema occupying the posterior half of the right hemisphere, which decreased after suspending growth hormone. After 15 months of low-dose administration of growth hormone, there is no evidence of further edema in the post-therapy radiological alterations.
1752-1947-3-17-2.jpg
PMC2633270_02_1752-1947-3-17-2.jpg
F2
November 2005, June 2006, December 2006, July 2007, and March 2008 (Figures 1 and 2). No recurrent disease was documented by these MRI studies, and the girl is currently in continuous complete response.